FWO Research Fund Flanders   Report issue

Foundation Phase 2
Founded: Brussels Belgium (2006)

Organization Overview

First Clinical Trial
2019
NCT03926936
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

FWO Research Fund Flanders

Active Ingredients

Drugs in Phase 2 Trials (1)

fulvestrant (faslodex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenosarcoma (Phase 2)

Endometrial Neoplasms (Phase 2)

Leiomyosarcoma (Phase 2)

Sarcoma, Endometrial Stromal (Phase 2)

Sex Cord-Gonadal Stromal Tumors (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1